Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Lee

Pediatric Otolaryngology Idaho Falls, ID Medical Doctor

NPI 1770796583 CMS profile 612875

3446 S 15Th E, Idaho Falls, ID 83404

Open in the dashboard

General payments

$1,881

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Richard Lee of Idaho Falls, ID is reported in the CMS Open Payments database as having received $1,881 across 27 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pediatric Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41 2
2023 General $103 4
2022 General $68 4
2021 General $1,554 12
2020 General $38 2
2019 General $77 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Lee
  • Pediatric Otolaryngology median
  • Middle half of Pediatric Otolaryngology
  • National median

In program year 2025, general payments to Richard Lee were reported at $41. Among 368 Pediatric Otolaryngology profiles paid that year, the median was $172 and the middle half received between $78 and $412.

Show as a table
Year Richard Lee Pediatric Otolaryngology median Middle half National median
2019 $77 $127 $51–$271 $163
2020 $38 $64 $31–$165 $114
2021 $1,554 $88 $26–$225 $132
2022 $68 $122 $43–$316 $149
2023 $103 $128 $52–$340 $160
2024 $0 $150 $65–$384 $164
2025 $41 $172 $78–$412 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $1,359 5 payments
  2. Intersect ENT, Inc. $76 3 payments
  3. Stryker Corporation $73 3 payments
  4. Inspire Medical Systems, Inc. $66 2 payments
  5. Cochlear Americas $60 2 payments
  6. Carestream Dental, LLC $58 2 payments
  7. Aerin Medical Inc. $31 2 payments
  8. OptiNose US, Inc. $29 2 payments
  9. DePuy Synthes Sales Inc. $25 1 payment
  10. Itamar Medical Inc $25 1 payment
  11. Other $79 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,230 4 payments
  2. Food and Beverage $651 23 payments
Products named General payments · program years 2019–2025
  1. CMF & Thoracic-None $993 2 payments
  2. TMS $262 2 payments
  3. TMJ Replacement System $105 1 payment
  4. LATERA $73 3 payments
  5. INSPIRE $66 2 payments
  6. Cochlear Nucleus CI632 cochlear implant with Slim Modiolar electrode $60 2 payments
  7. Baha BI300 implant 4 mm $60 2 payments
  8. Cochlear Osia OSI200 Implant $60 2 payments
  9. SINUVA $56 2 payments
  10. SCOPIS ENT $39 1 payment
  11. Other $317 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

107

Median for Otolaryngology: 297

Drug cost

$1,271

Median for Otolaryngology: $6,314

Branded share of claims

15%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofloxacin Generic 19 $488
Ipratropium Bromide Generic 11 $359
Fluticasone Propionate Generic 26 $170
Mupirocin Generic 21 $134
Cephalexin Generic 14 $77
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$52,124

Medicare's payments for the services billed

Medicare patients

248

Average age 75

Services billed

740

144 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 48%
Diabetes 34%
Chronic kidney disease 29%
Depression 23%
Ischemic heart disease 20%
Atrial fibrillation 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record